Our initial partnership with Fresenius Medical Care included the exclusive licence agreement for the commercialisation of Venofer® ▼(iron sucrose) and Ferinject® ▼ (iron carboxymaltose) for iron deficiency and iron deficiency anaemia in haemodialysis in US, Europe, the Middle East, Africa and Latin America.
Vifor Fresenius Medical Care Renal Pharma Ltd.
In December 2010 we extended our partnership with Fresenius Medical Care (FMC) announced through the creation of a specialty pharmaceuticals company. Vifor Fresenius Medical Care Renal Pharma Ltd, which is owned 55 percent by Galenica, develops and commercialises innovative and high quality products to improve the lives of patients suffering from chronic kidney disease (CKD) worldwide. The products of Vifor Fresenius Medical Care Renal Pharma Ltd. include Venofer® and Ferinject® in the field of dialysis and pre-dialysis (CKD stage III – V) as well as Velphoro® ▼, an iron-based phosphate binder.
Within the Vifor Fresenius Medical Care Renal Pharma Ltd. partnership, Vifor Pharma contributes its expertise in phosphate binding and global leadership in iron replacement therapy whilst FMC provides access to its network of dialysis centres.
The Old Stables, Bagshot Park, Bagshot
Surrey-UK GU19 5PJ
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/
Adverse Events should also be reported to
Vifor Pharma UK Ltd.